Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies - PubMed (original) (raw)

. 2020 Mar 5;180(5):895-914.e27.

doi: 10.1016/j.cell.2020.02.019.

Priscila O De Lima 1, Jazmina L Gonzalez Cruz 1, Blerida Banushi 1, Godwins Echejoh 1, Lingbo Hu 1, Shannon R Joseph 1, Benedict Lum 1, James Rae 2, Jake S O'Donnell 1, Lilia Merida de Long 1, Satomi Okano 1, Brigid King 1, Rachael Barry 1, Davide Moi 1, Roberta Mazzieri 1, Ranjeny Thomas 1, Fernando Souza-Fonseca-Guimaraes 1, Matthew Foote 3, Adam McCluskey 4, Phillip J Robinson 5, Ian H Frazer 1, Nicholas A Saunders 1, Robert G Parton 2, Riccardo Dolcetti 1, Katharine Cuff 6, Jennifer H Martin 7, Benedict Panizza 6, Euan Walpole 6, James W Wells 1, Fiona Simpson 8

Affiliations

• PMID: 32142680
• DOI: 10.1016/j.cell.2020.02.019

Free article

Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies

Hui Yi Chew et al. Cell. 2020.

Free article

Abstract

A safe and controlled manipulation of endocytosis in vivo may have disruptive therapeutic potential. Here, we demonstrate that the anti-emetic/anti-psychotic prochlorperazine can be repurposed to reversibly inhibit the in vivo endocytosis of membrane proteins targeted by therapeutic monoclonal antibodies, as directly demonstrated by our human tumor ex vivo assay. Temporary endocytosis inhibition results in enhanced target availability and improved efficiency of natural killer cell-mediated antibody-dependent cellular cytotoxicity (ADCC), a mediator of clinical responses induced by IgG1 antibodies, demonstrated here for cetuximab, trastuzumab, and avelumab. Extensive analysis of downstream signaling pathways ruled out on-target toxicities. By overcoming the heterogeneity of drug target availability that frequently characterizes poorly responsive or resistant tumors, clinical application of reversible endocytosis inhibition may considerably improve the clinical benefit of ADCC-mediating therapeutic antibodies.

Keywords: antibody-dependent cellular cytotoxicity; avelumab; cetuximab; endocytosis; epidermal growth factor receptor; monoclonal antibody therapy; natural killer cell; prochlorperazine; programmed death ligand 1; trastuzumab.

Copyright © 2020 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests other than the following: The avelumab work was conducted under investigator-initiated contract with Merck KGaA. The costs of the experiments were paid for by Merck KGaA and avelumab supplied by Merck. This work utilizes technology subject to the following patents: 2015 WO2014063206-A1 “classifying epidermal growth factor receptor positive tumor into subtype eg epidermal growth factor receptor antagonist sensitive subtype, involves analyzing ligand-induced epidermal growth factor receptor internalization status of tumor.” Simpson, F., Saunders, N.A.; 2015 WO2014063205-A1 “composition useful in kit for treating tumor, preferably cell surface antigen positive tumor eg cancerous tumors, comprises antibody that binds to cell surface antigen of tumor and inhibitor of receptor mediated endocytosis” Simpson, F., Saunders, N.A.

Comment in

• Boosting Cytotoxic Antibodies against Cancer.
  Gauthier L, Vivier E. Gauthier L, et al. Cell. 2020 Mar 5;180(5):822-824. doi: 10.1016/j.cell.2020.02.025. Cell. 2020. PMID: 32142673
• Blocking endocytosis gives therapeutic antibodies a boost.
  Wrighton KH. Wrighton KH. Nat Rev Drug Discov. 2020 Apr;19(4):237. doi: 10.1038/d41573-020-00041-z. Nat Rev Drug Discov. 2020. PMID: 32161369 No abstract available.

Similar articles

• Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes.
  Namboodiri AM, Pandey JP. Namboodiri AM, et al. Clin Exp Immunol. 2011 Dec;166(3):361-5. doi: 10.1111/j.1365-2249.2011.04477.x. Clin Exp Immunol. 2011. PMID: 22059994 Free PMC article.
• Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
  Kim Y, Lee SH, Kim CJ, Lee JJ, Yu D, Ahn S, Shin DJ, Kim SK. Kim Y, et al. BMC Vet Res. 2019 Oct 14;15(1):339. doi: 10.1186/s12917-019-2068-5. BMC Vet Res. 2019. PMID: 31610784 Free PMC article.
• GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
  Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, Bossenmaier B, Mueller HJ, Umaña P. Gerdes CA, et al. Clin Cancer Res. 2013 Mar 1;19(5):1126-38. doi: 10.1158/1078-0432.CCR-12-0989. Epub 2012 Dec 3. Clin Cancer Res. 2013. PMID: 23209031
• The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients.
  Monteverde M, Milano G, Strola G, Maffi M, Lattanzio L, Vivenza D, Tonissi F, Merlano M, Lo Nigro C. Monteverde M, et al. Crit Rev Oncol Hematol. 2015 Aug;95(2):179-90. doi: 10.1016/j.critrevonc.2015.02.014. Epub 2015 Mar 12. Crit Rev Oncol Hematol. 2015. PMID: 25819749 Review.
• Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.
  Hamilton G, Rath B. Hamilton G, et al. Expert Opin Biol Ther. 2017 Apr;17(4):515-523. doi: 10.1080/14712598.2017.1294156. Epub 2017 Feb 22. Expert Opin Biol Ther. 2017. PMID: 28274143 Review.

Cited by

• Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine.
  O'Donnell JS, Isaacs A, Jakob V, Lebas C, Barnes JB, Reading PC, Young PR, Watterson D, Dubois PM, Collin N, Chappell KJ. O'Donnell JS, et al. Front Immunol. 2022 Sep 2;13:976968. doi: 10.3389/fimmu.2022.976968. eCollection 2022. Front Immunol. 2022. PMID: 36119058 Free PMC article.
• The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID-19.
  Stip E, Rizvi TA, Mustafa F, Javaid S, Aburuz S, Ahmed NN, Abdel Aziz K, Arnone D, Subbarayan A, Al Mugaddam F, Khan G. Stip E, et al. Front Pharmacol. 2020 Dec 16;11:577678. doi: 10.3389/fphar.2020.577678. eCollection 2020. Front Pharmacol. 2020. PMID: 33390948 Free PMC article.
• Role of Endocytosis Proteins in Gefitinib-Mediated EGFR Internalisation in Glioma Cells.
  Cruz Da Silva E, Choulier L, Thevenard-Devy J, Schneider C, Carl P, Rondé P, Dedieu S, Lehmann M. Cruz Da Silva E, et al. Cells. 2021 Nov 21;10(11):3258. doi: 10.3390/cells10113258. Cells. 2021. PMID: 34831480 Free PMC article.
• Blocking endocytosis gives therapeutic antibodies a boost.
  Wrighton KH. Wrighton KH. Nat Rev Drug Discov. 2020 Apr;19(4):237. doi: 10.1038/d41573-020-00041-z. Nat Rev Drug Discov. 2020. PMID: 32161369 No abstract available.
• Agonistic anti-DCIR antibody inhibits ITAM-mediated inflammatory signaling and promotes immune resolution.
  Chen L, Patil S, Barbon J, Waire J, Laroux S, McCarthy D, Pratibha M, Zhong S, Dong F, Orsi K, Nguyen G, Yang Y, Crosbie N, Dominguez E, Deora A, Veldman G, Westmoreland S, Jin L, Radstake T, White K, Wei HJ. Chen L, et al. JCI Insight. 2024 May 23;9(12):e176064. doi: 10.1172/jci.insight.176064. JCI Insight. 2024. PMID: 38781017 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)

• Research Materials

  • NCI CPTC Antibody Characterization Program